Recent studies (2022–2025) have established that TP53 mutations, particularly gain-of-function (GOF) mutants, orchestrate an immune-privileged sanctuary in tumors by reshaping the tumor microenvironment (TME) toward immunosuppression. Here, TP53 is linked to neoplasm.